Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

PharmaGap Inc V.GAP

Healthcare Biotechnology


TSXV:GAP - Post by User

PharmaGap Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Post by theq_fezon Jul 29, 2010 10:24am
454 Views
Post# 17306607

News in a few days

News in a few daysThe news will be toxicity  results    -    or NRC & Tandem Lab results.
Both are expected in July.
Toxicity results are very important for Licensing interest, and so far Gap has confirmed very little to no toxicity.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities